Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology.

Education Europe Masters Molecular pathology Standardization

Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
02 Oct 2024
Historique:
received: 29 06 2024
accepted: 21 09 2024
revised: 26 08 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 1 10 2024
Statut: aheadofprint

Résumé

Despite advancements in precision medicine, many cancer patients globally, particularly those in resource-constrained environments, face significant challenges in accessing high-quality molecular testing and targeted therapies. The considerable heterogeneity in molecular testing highlights the urgent need to harmonize practices across Europe and beyond, establishing a more standardized and consistent approach in MP laboratories. Professionals, especially molecular pathologists, must move beyond traditional education to cope with this heterogeneity. This perspective addresses critical issues in molecular pathology (MP), such as limited access to high-quality molecular testing, leading to disparities in cancer treatment, and the consequences of inconsistent practices. Recognizing the necessity for a standardized framework for education to address these issues, educational programs play a pivotal role in updating professionals' skills to achieve standardization in MP. European experts from the Steering Committee, the Pathology Section of the European Union of Medical Specialists, and the European Society of Pathology have proposed creating a comprehensive Master's degree program called the "European Masters in Molecular Pathology" (EMMP). This program emerges as a strategic response to the demand for a specialized and standardized framework for education in MP, catering to professionals who concurrently work and study. The program's design aligns with evidence-based education methods, ensuring effective learning and engagement while integrating computational pathology to analyze complex molecular data, enhance diagnostic accuracy, and improve treatment outcomes. EMMP's structured curriculum, strategic partnerships, and regular updates underscore its significance in standardizing MP practices. Exploring future developments, this perspective delves into technology integration and interdisciplinary collaboration, anticipating ongoing advances and harmonization. Challenges and future directions in MP education are discussed, emphasizing the necessity for dynamic curriculum updates, seamless technology integration, and interdisciplinary cooperation. This perspective underscores EMMP's pivotal role in preparing pathologists for this dynamic field, advocating continuous advancements in education and training to uphold excellence in MP practices and maintain the highest patient care standards.

Identifiants

pubmed: 39354109
doi: 10.1007/s00428-024-03933-2
pii: 10.1007/s00428-024-03933-2
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-23-IAHU-007

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Mateo J, Steuten L, Aftimos P, Andre F, Davies M, Garralda E et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28:658–665
doi: 10.1038/s41591-022-01717-2 pubmed: 35440717
Akhoundova D, Rubin MA (2022) Clinical application of advanced multi-omics tumor profiling: shaping precision oncology of the future. Cancer Cell 40:920–938
doi: 10.1016/j.ccell.2022.08.011 pubmed: 36055231
Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J et al (2022) Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer 176:70–77
doi: 10.1016/j.ejca.2022.09.005 pubmed: 36194905
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R et al (2024) Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Reg Health - Europe 38:100838
doi: 10.1016/j.lanepe.2024.100838 pubmed: 38476742
Hofman P, Calabrese F, Kern I, Adam J, Alarcao A, Alborelli I et al (2023) Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 8:101628
doi: 10.1016/j.esmoop.2023.101628 pubmed: 37713929 pmcid: 10594022
Bruno DS, Hess LM, Li X, Su EW, Patel M (2022) Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States. JCO Precis Oncol 6:e2100427
doi: 10.1200/PO.21.00427 pubmed: 35737912
Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D et al (2023) Empowering quality data - the Gordian knot of bringing real innovation into healthcare system. Diagnosis (Berl) 10:140–157
doi: 10.1515/dx-2022-0115 pubmed: 36548810
Normanno N, Apostolidis K, de Lorenzo F, Beer PA, Henderson R, Sullivan R et al (2022) Cancer biomarkers in the era of precision oncology: addressing the needs of patients and health systems. Semin Cancer Biol 84:293–301
doi: 10.1016/j.semcancer.2021.08.002 pubmed: 34389490
Horgan D, Van den Bulcke M, Malapelle U, Troncone G, Normanno N, Capoluongo ED et al (2024) Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems. Heliyon 10:e23914
doi: 10.1016/j.heliyon.2023.e23914 pubmed: 38234913
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31:1491–1505
doi: 10.1016/j.annonc.2020.07.014 pubmed: 32853681
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A et al (2023) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:339–357
doi: 10.1016/j.annonc.2022.12.009 pubmed: 36872130
Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D et al (2023) Framework for adoption of next-generation sequencing (NGS) globally in the oncology area. Healthcare (Basel) 11:431
doi: 10.3390/healthcare11030431 pubmed: 36767006
Moulin P, Grunberg K, Barale-Thomas E, der Laak JV (2021) IMI-Bigpicture: a central repository for digital pathology. Toxicol Pathol 49:711–713
doi: 10.1177/0192623321989644 pubmed: 33571073
Matias-Guiu X, Stanta G, Carneiro F, Ryska A, Hoefler G, Moch H (2020) The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. Virchows Arch 476:491–497
doi: 10.1007/s00428-020-02757-0 pubmed: 32124002 pmcid: 7156353
Stenzinger A, Moltzen EK, Winkler E, Molnar-Gabor F, Malek N, Costescu A et al (2023) Implementation of precision medicine in healthcare-a European perspective. J Intern Med 294:437–454
doi: 10.1111/joim.13698 pubmed: 37455247
Laudadio J, McNeal JL, Boyd SD, Le LP, Lockwood C, McCloskey CB et al (2015) Design of a genomics curriculum: competencies for practicing pathologists. Arch Pathol Lab Med 139:894–900
doi: 10.5858/arpa.2014-0253-CP pubmed: 26125429
Arcila ME, Snow AN, Akkari YMN, Chabot-Richards D, Pancholi P, Tafe LJ (2022) Molecular pathology education: a suggested framework for primary care resident training in genomic medicine: a report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn 24:430–441
doi: 10.1016/j.jmoldx.2021.12.013 pubmed: 35304347
Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjo A, Rouleau E et al (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67:923–931
doi: 10.1136/jclinpath-2014-202404 pubmed: 25012948
Platonova RI, Orekhovskaya NA, Dautova SB, Martynenko EV, Kryukova NI, Demir S (2022) Blended learning in higher education: diversifying models and practical recommendations for researchers. Frontiers in Education. [Review] 7.  https://doi.org/10.3389/feduc.2022.957199
Rangachari D, Im A, Brondfield S (2022) Moving from theory to practice in oncology education when virtual is your reality. Am Soc Clin Oncol Educ Book 42:1–10
pubmed: 35471835
Jang HY, Kim HJ (2020) A meta-analysis of the cognitive, affective, and interpersonal outcomes of flipped classrooms in higher education. Educ Sci 10:115
doi: 10.3390/educsci10040115
Horgan D, Curigliano G, Riess O, Hofman P, Buttner R, Conte P et al (2022) Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe. J Pers Med 12:72
doi: 10.3390/jpm12010072 pubmed: 35055387 pmcid: 8780351
Horgan D, Bulcke MVD, Malapelle U, Normanno N, Capoluongo ED, Prelaj A et al (2024) Aligning cancer research priorities in Europe with recommendations for conquering cancer: a comprehensive analysis. Healthcare (Basel) 12:259
doi: 10.3390/healthcare12020259 pubmed: 38275541

Auteurs

Marius Ilié (M)

Laboratory of Clinical and Experimental Pathology, Hospital-Related Biobank BB0033-00025, Nice University Hospital, University Côte d'Azur, FHU OncoAge, IHU RespirERA, 06000, Nice, France. ilie.m@chu-nice.fr.

Vivien Lake (V)

Center for Active Learning and MSc International Office, IDEX Université Côte d'Azur, Nice, France.

Enrique de Alava (E)

Institute of Biomedicine of Sevilla, IBiS/Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, 41013, Seville, Spain.
Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41009, Seville, Spain.

Serena Bonin (S)

Molecular Histopathology Laboratory, DSM-Department of Medical Sciences, University of Trieste, Trieste, Italy.

Sandra Chlebowski (S)

Center for Active Learning and MSc International Office, IDEX Université Côte d'Azur, Nice, France.

Aurélie Delort (A)

Center for Active Learning and MSc International Office, IDEX Université Côte d'Azur, Nice, France.

Elisabeth Dequeker (E)

Department of Public Health and Primary Care, Biomedical Quality Assurance Research Unit, University of Leuven, Kapucijnenvoer 7 blok g - bus 7001, 3000, Leuven, Belgium.

Raed Al-Dieri (R)

European Society of Pathology, Brussels, Belgium.

Arjan Diepstra (A)

Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Olli Carpén (O)

Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.

Catarina Eloy (C)

Pathology Laboratory, Institute of Molecular Pathology and Immunology of the University of Porto - IPATIMUP, Porto, Portugal.

Ambrogio Fassina (A)

Pathology Department, Pathology Section of UEMS, University of Padova, Padova, Italy.

Falko Fend (F)

Institute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.

Pedro L Fernandez (PL)

Pathology Department, Hospital Germans Trias i Pujol, IGTP, Autonomous University of Barcelona, Badalona, Spain.

Gregor Gorkiewicz (G)

Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.

Simon Heeke (S)

Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Rui Henrique (R)

Department of Pathology and Cancer Biology and Epigenetics Group - CI-IPOP@RISE (Health Research Network) Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) & Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, Portuguese Oncology Institute of Porto (IPO Porto), University of Porto, Porto, Portugal.

Gerald Hoefler (G)

Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.

Pablo Huertas (P)

Departamento de Genética, Universidad de Sevilla, Sevilla, Spain.
Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad de Sevilla-CSIC-Universidad Pablo de Olavide, 41092, Sevilla, Spain.

Michael Hummel (M)

Molecular Diagnostics Institute of Pathology Charité, Universitätsmedizin Berlin, Berlin, Germany.

Karl Kashofer (K)

Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.

Jeroen van der Laak (J)

Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands.

Rocio Martinez de Pablos (RM)

Departamento de Genética, Universidad de Sevilla, Sevilla, Spain.
Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad de Sevilla-CSIC-Universidad Pablo de Olavide, 41092, Sevilla, Spain.

Fernando Schmitt (F)

Department of Pathology, Faculty of Medicine of University of Porto, CINTESIS@-RISE, Health Research Network, Porto, Portugal.
Molecular Unit, IPATIMUP, University of Porto, Porto, Portugal.

Ed Schuuring (E)

Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Giorgio Stanta (G)

Department of Public Health and Primary Care, Biomedical Quality Assurance Research Unit, University of Leuven, Kapucijnenvoer 7 blok g - bus 7001, 3000, Leuven, Belgium.
Biobanking and Molecular Pathobiology Working Group OECI, OECI, Brussels, Belgium.

Wim Timens (W)

Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Benedikt Westphalen (B)

Comprehensive Cancer Center Munich & Department of Medicine III, Ludwig-Maximilian University of Munich, Munich, Germany.
German Cancer Consortium (DKTK Partner Site Munich), Heidelberg, Germany.

Paul Hofman (P)

Laboratory of Clinical and Experimental Pathology, Hospital-Related Biobank BB0033-00025, Nice University Hospital, University Côte d'Azur, FHU OncoAge, IHU RespirERA, 06000, Nice, France.

Classifications MeSH